“We are disappointed for patients and their families awaiting additional treatment options in this setting.” Robert W. Duggan, chairman and co-chief executive officer, Summit Therapeutics
FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit
Key Takeaways
- FDA prioritized statistically significant OS over PFS in the benefit-risk calculus for this post-EGFR TKI setting, concluding that PFS gain without OS significance was insufficient for approval.
- HARMONi randomized 438 patients to ivonescimab 20 mg/kg Q3W or placebo with carboplatin/pemetrexed; median PFS was 6.8 vs 4.4 months (HR 0.52; P<.0001).
FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.
FDA has issued a complete response letter (CRL) declining to approve ivonescimab, Summit Therapeutics and Akeso’s PD-1×VEGF bispecific antibody, in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with an EGFR tyrosine kinase inhibitor (TKI).¹˒² The decision means the first PD-1×VEGF bispecific to seek US approval will not reach the market in this setting for now.
FDA concluded that the biologics license application (BLA) could not be approved in its current form because Summit had not established substantial evidence of effectiveness without a statistically significant improvement in overall survival (OS).² The agency also determined that a progression-free survival (PFS) benefit without a significant OS benefit does not support a favorable benefit-risk profile.²
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert W. Duggan, chairman and co-chief executive officer of Summit Therapeutics.²
What did the HARMONi trial show?
The BLA was based on HARMONi (NCT06396065), a global, randomized, double-blind phase 3 trial with dual primary endpoints of OS and PFS.² The trial randomized 438 patients 1:1 to ivonescimab 20 mg/kg or placebo every three weeks, each with carboplatin and pemetrexed.²
HARMONi met its PFS endpoint. Median PFS was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months with placebo plus chemotherapy (hazard ratio [HR], 0.52; 95% CI, 0.41-0.66; P<.0001).²˒³ Median OS was 16.8 months vs 14.0 months, but the primary OS analysis did not reach statistical significance (HR, 0.79; 95% CI, 0.62-1.01; P=.0570).²˒³ A longer follow-up analysis in Western patients showed an HR of 0.78 (95% CI, 0.62-0.98; nominal P=.0332).²
The ivonescimab arm also had more serious treatment-related adverse events (28.0% vs 15.1%) and grade 3 or higher treatment-related adverse events (50.0% vs 42.2%).²
Why does overall survival matter?
FDA’s decision underscores how heavily the agency weighs survival data in oncology. Summit noted that no FDA-approved regimens in this setting have demonstrated a statistically significant OS benefit.⁴ Generating survival data, however, requires larger and longer trials. In a
What does it mean for the PD-1×VEGF class?
Ivonescimab is already approved in China, where Akeso has reported positive phase 3 results in multiple settings. In August, China’s National Medical Products Administration
The CRL adds uncertainty to a class that has attracted major investment from large pharmaceutical companies. Pfizer, for example, licensed 3SBio’s PD-1×VEGF bispecific tivunatamig, which BioPharm International reported
What happens next?
Duggan said the decision does not change the company’s view of the drug. “With 5 positive phase 3 studies between Summit and Akeso, nothing changes,” he said, adding that Summit “will continue through our expansive clinical development program.”² Ivonescimab is not approved in any of Summit’s license territories, which include the US and Europe.⁵
References
Summit Therapeutics provides update regarding ivonescimab biologics license application . News release. Summit Therapeutics; November 15, 2026. Accessed November 16, 2026.FDA issues CRL to ivonescimab plus chemo for locally advanced or metastatic NSCLC . OncLive. Published November 16, 2026. Accessed November 16, 2026.- Goldman JW, Passaro A, Laskin J, et al.
Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi . Presented at: 2025 IASLC World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 4808. Accessed November 16, 2026. FDA provides CRL to ivonescimab/chemotherapy for pretreated EGFR+ NSCLC . CancerNetwork. Published November 16, 2026. Accessed November 16, 2026.- Summit Therapeutics Inc.
Form 8-K . US Securities and Exchange Commission. Filed February 2026. Accessed November 16, 2026.
Related to this article









